CureVac N.V. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was EUR 16.48 million compared to EUR 11.21 million a year ago. Net loss was EUR 48.68 million compared to EUR 47.57 million a year ago. Basic loss per share from continuing operations was EUR 0.22 compared to EUR 0.25 a year ago.
For the nine months, sales was EUR 31.19 million compared to EUR 55.73 million a year ago. Net loss was EUR 173.51 million compared to EUR 120.25 million a year ago. Basic loss per share from continuing operations was EUR 0.79 compared to EUR 0.64 a year ago.